Heptares Therapeutics Limited

Astex Therapeutics Limited

Nxera Pharma UK Limited

Novartis Ag

Astrazeneca Ab

Glaxo Group Limited

Other

Allergan Pharmaceuticals Therapeutics International Limited

Nxera Pharma UK Limitied

Miles Stuart Congreve

Giles Albert Brown

Benjamin Gerald Tehan

Mark Pickworth

Julie Elaine Cansfield

John Andrew Christopher

Michael Alistair O'Brien

Christopher William Murray

Jonathan Stephen Mason

Barry John Teobald

Sarah Joanne Aves

Sarah Joanne Bucknell

Francesca Deflorian

Gianni Chessari

Maria Grazia Carr

Martyn Frederickson

Andrew James Woodhead

Mark David Rackham

Eva Figueroa Navarro

Nigel Alan Swain

Alison Jo-Anne Woolford

Robert Downham

Christine Mary Richardson

Stephen Philippe Andrews

Theresa Rachel Phillips

Andrew Madin

Valerio Berdini

Gordon Saxty

Gilbert Besong

Sukhbinder Singh Klair

Steven Howard

Bharat Lagu

Charlotte Mary Griffiths-Jones

Christopher Thomas Brain

Adrian Liam Gill

Emma Vickerstaffe

Claudio Dagostin

Owen Callaghan

Paul Mortenson

Yue Ping Li

Gerard Martin Paul Giblin

Steven John Woodhead

Moo Je Sung

Andrew David Cansfield

Patrick René Angibaud

Santosh Shripad Kulkarni

Ann Louise Walker

Troy Douglas Smith

Shawn Donald Johnstone

Richard David Taylor

Karl Henrik Edman

David Livermore

Laszlo Rakos

Guo He

Jörg Holenz

Mark Mills

Wojciech Wrona

Marc O'Reilly

Yipin Lu

Ying Hou

Anil Patel

Kathryn White

Rajdeep Kaur Nijjar

Andrew Pike

Clinton Alan Brooks

John Graham Cumming

Frank Xinhe Wu

Sahil Patel

Hongming Chen

Dean Gordon Brown

Brian John Williams

Michael Luzzio

Eddy Jean Edgard Freyne

Stefan Berg

Paul Graham Wyatt

Lawrence Blas Perez

Andrew McMurtrie Mason

Fan Yang

David Richard Newell

Annika Kers

Christine Hiu-Tung Chen

Charlotte Fieldhouse

Karin Kolmodin

Neil Thomas Thompson

John Francis Lyons

Christopher Charles Frederick Hamlett

Young Shin Cho

Yaping Wang

John William Giraldes

Steven Woodhead

Geraint Jones

Neil Derek Miller

Phil Edwards

Andrew William Phillips

Sunkyu Kim

Tom Cornelis Hortense Govaerts

James Arnold

Susan Roomans

Steven Douglas Hiscock

Didier Rotticci

The disclosures herein relate to novel compounds of formula I: and salts thereof, wherein X, Y, A, Ring B, R, R, R, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EPreceptors.

Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases

The disclosures herein relate to novel compounds of formula (1): and salts thereof, wherein R, AA, AA2, LysR, X and Y are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with Glucagon-like peptide-1 (GLP-1) receptors.

GLP-1 receptor antagonists

The disclosures herein relate to novel compounds of formula wherein R, R, Rand Rand n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mGlu5 receptor function.

4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators

The disclosures herein relate to novel compounds of formula (1): (1) and salts thereof, wherein A, X, R, R, R, R, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EPreceptors.

Prostaglandin EPreceptor antagonist compounds

The disclosures herein relate to novel compounds of Formula (1); and salts thereof, wherein A, A, Q, X, R, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

CGRP antagonist compounds

The disclosures herein relate to novel compounds of formula (I): and salts thereof, wherein W; X; Y; Z; R; R; Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Orexin 1 receptor antagonists

The disclosures herein relate to novel compounds of formula (1) and salts thereof, wherein V; W; X; Y; Z; R; R; R; Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

Oxexin 1 receptor antagonists

Pyrazole derivatives as H4 antagonist compounds

The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

This invention related to compounds having activity as muscarinic Mor Mand Mreceptor agonists which are useful in the treatment of diseases mediated by the muscarinic Mand Mreceptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where X; X; X; X; Y; Z; n, Rand Rare defined herein.

Quinolinone and benzoxazine derivatives as muscarinic Mand/or Mreceptor agonists

This invention relates to compounds that are agonists of the muscarinic Mreceptor and which are useful in the treatment of muscarinic Mreceptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where m, p, q, W, Z, Y, X, X, R, R, Rand Rare as defined herein.

Muscarinic receptor agonists

The disclosures herein relate to novel compounds of formula

CGRP receptor antagonists

According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A-Aor, particularly, the Areceptor. A process for the preparation of the compound, pharmaceutical compositions comprising the compound, and methods of treatment comprising administration of an effective amount of the compound are also disclosed.

1,2,4-triazine-4-amine derivatives

This invention relates to compounds that are agonists of the muscarinic Mand Mreceptor and which are useful in the treatment of diseases mediated by the muscarinic Mand/or Mreceptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (1): and salts thereof.

Pharmaceutical compounds

The disclosures herein relate to novel compounds of formula (1):(1) and salts thereof, wherein W, X, Y, Z, m, n, q, R, R, R, R, Rand Rare defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with somatostatin receptors.

Cyclohexapeptides as selective somatostatin SST5 receptor agonists

Growing community of inventors

Cambridge, United Kingdom

Miles Stuart Congreve